News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Drug Development
US Halts New Enrollment in GlaxoSmithKline’s Avandia Trial
July 22, 2010
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
Reuters -- U.S. health officials have halted enrollment of new patients in a clinical trial of GlaxoSmithKline Plc's (GSK.L) diabetes pill Avandia while regulators consider if the drug should stay on the market.
Twitter
LinkedIn
Facebook
Email
Print
Clinical research
Postmarket research
GSK
MORE ON THIS TOPIC
Gene editing
Lilly’s Verve gambit pays off as base editor cuts cholesterol in early study
May 26, 2026
·
2 min read
·
Tristan Manalac
Antibody-drug conjugate (ADC)
Kelun-Merck validate TROP2-Keytruda pairing in lung cancer with improved survival
May 22, 2026
·
3 min read
·
Annalee Armstrong
Parkinson’s disease
Biogen, Denali pull plug on Parkinson’s program after mid-stage flop
May 22, 2026
·
2 min read
·
Tristan Manalac
Postmarket research
Update: Reversal after 20 deaths allows new Japan patients to take Amgen’s rare disease drug Tavneos
May 21, 2026
·
3 min read
·
Tristan Manalac
